Keywords Dupilumab, EosinophilicEsophagitis, Benefit Assessment Extract of dossier assessment A23-23 Version 1.0 Dupilumab ( eosinophilicoesophagitis) 28 June 2023 Institute for Quality and Efficiency in Health Care (IQWiG) - I.1 - Part I: Benefit assessment Extract of dossier assessment A23-23 Version 1.0 Dupilumab ( eosinophilicoesophagitis) 28 June 2023 Institute for Quality and Efficiency Dupilumab (eosinophilicoesophagitis) ' Benefit assessment according to '35a Social Code Book V 1 Translation of Sections I 1 to I 6 of the dossier assessment Dupilumab (eosinophile Ösophagitis) – Nutzenbewertung gemäß § 35a SGB V. Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative
Dupilumab (Dupixent) - eosinophilicesophagitis Published 10 June 2024 Statement of advice SMC2682 dupilumab solution for injection in pre-filled pen and syringe (Dupixent®) Sanofi 10 May 2024 ADVICE: in the absence of a submission from the holder of the marketing authorisation dupilumab (Dupixent®) is not recommended for use within NHSScotland. Indication under review: treatment of eosinophilicesophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland. Advice context: No part
Cendakimab for eosinophilicoesophagitis in people aged 12 years and over Cendakimab for eosinophilicoesophagitis in people aged 12 years and over - NIHR Innovation Observatory * Who we are * What we do * Our Networks * Engage * Events * News * Resources Get in touch * * A world leading Horizon Scanning Facility The NIHR Innovation Observatory is a world leading health and care innovation * What we do * Emerging horizon * Transitional horizon * Imminent horizon * Our Networks * Our Stakeholders * Our Work with NICE * Health & Life Sciences Ecosystem * Engage * Industry * Public Involvement * Capacity Building * Events * News * Resources * Contact 23 July 2024 Cendakimab for eosinophilicoesophagitis in people aged 12 years and overEosinophilic oesophagitis (EoE) is a chronic disorder
Eosinophilicoesophagitis: the advantages of orodispersible budesonide (Jorveza) Prescrire IN ENGLISH - Spotlight ''Eosinophilicoesophagitis: the advantages of orodispersible budesonide (Jorveza°)'', 1 February 2022 {1}##LOC[OK]## {1} ##LOC[OK]## ##LOC[Cancel]## {1}##LOC[OK]####LOC[Cancel]## Register online| Log in| My Prescrire Issue contents * Current issue * Last 12 issues * All issues * Subscribe now * Solidarity Subscription Rate * Subscribers: register online * Prescrire's other products * Free Special Edition * Sign up to receive the newsletter english.prescrire.org > Spotlight > 100 most recent > Eosinophilicoesophagitis: the advantages of orodispersible budesonide (Jorveza°) SpotlightEvery month, the subjects in Prescrire’s Spotlight. 100 most recent: 1|10|20|30|40|50|60
BSG and BSPGHAN joint consensus guidelines on the diagnosis and management of eosinophilicoesophagitis in children and adults British Society of Gastroenterology (BSG) and British Society of Paediatric Gastroenterology, Hepatology and Nutrition (BSPGHAN) joint consensus guidelines on the diagnosis and management of eosinophilicoesophagitis in children and adults =============================================================================================================================================================================================================================================== * Anjan Dhar * Hasan N Haboubi * Stephen E Attwood * Marcus K H Auth * Jason M Dunn * Rami Sweis * Danielle Morris * Jenny Epstein * Marco R Novelli * Hannah Hunter * Amanda Cordell * Sharon Hall * Jamal O Hayat * Kapil Kapur * Andrew Robert Moore * Carol Read * Sarmed S Sami * Paul J Turner * Nigel J Trudgill ## Abstract **Background** Eosinophilicoe..
Algorithm for dietary management of eosinophilicoesophagitis (EoE) in paediatrics Algorithm for dietary management of eosinophilicoesophagitis (EoE) in paediatrics*Lucy Jackman & Kerryn Moolenschot on behalf of the BSPGHAN EoEworking group Histological diagnosis of EoEconfirmed by a gastroenterologistTreatment options* discussed with patient / parent / guardian -PPI, topical steroids /pediatric-eosinophilic-esophagitis-symptom-severity-module-version-2.02 food exclusion diet (2FED) for at least8 -12 weeks(milk, + / -wheat or egg) then repeat endoscopyIf not in remission then proceed to 4 food exclusion (4FED) for at least8 -12 weeks (milk, egg, wheat, soya) then repeat endoscopy If not in remission then proceed to 6 food exclusion (6FED) for at least 8 -12 weeks (milk, egg, wheat
Eosinophil Depletion with Benralizumab for EosinophilicEsophagitis. Benralizumab is an eosinophil-depleting anti-interleukin-5 receptor α monoclonal antibody. The efficacy and safety of benralizumab in patients with eosinophilicesophagitis are unclear. In a phase 3, multicenter, double-blind, randomized, placebo-controlled trial, we assigned patients 12 to 65 years of age with symptomatic and histologically active eosinophilicesophagitis in a 1:1 ratio to receive subcutaneous benralizumab (30 mg) or placebo every 4 weeks. The two primary efficacy end points were histologic response (≤6 eosinophils per high-power field) and the change from baseline in the score on the Dysphagia Symptom Questionnaire (DSQ; range, 0 to 84, with higher scores indicating more frequent or severe dysphagia) at week 24
Dupilumab for EosinophilicEsophagitis in Patients 1 to 11 Years of Age. Dupilumab is a human monoclonal antibody that blocks interleukin-4 and interleukin-13 pathways and has shown efficacy in five different atopic diseases marked by type 2 inflammation, including eosinophilicesophagitis in adults and adolescents. In this phase 3 trial, we randomly assigned, in a 2:2:1:1 ratio, patients 1 to 11 years of age with active eosinophilicesophagitis who had had no response to proton-pump inhibitors to 16 weeks of a higher-exposure or lower-exposure subcutaneous dupilumab regimen or to placebo (two groups) (Part A). At the end of Part A, eligible patients in each dupilumab group continued the same regimen and those in the placebo groups were assigned to higher-exposure or lower-exposure
S2k guideline Gastroesophageal reflux disease and eosinophilicesophagitis of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) S2k guideline Gastroesophageal reflux disease and eosinophilicesophagitis of the German Society for Gastroenterology, Digestive and Metabolic Diseases (DGVS) March 2023 - AWMF Register Number: 021 - 013 Authors Ahmed Madisch1,2, Herbert Correspondence address Prof. Dr. med. habil. Ahmed Madisch Center Gastroenterology Bethany Agaplesion Bethanien Hospital Im Prüfling 21-25 60389 Frankfurt madisch@gastroenterologie-frankfurt.de publiziert bei published at: Update S2k guideline Gastroesophageal reflux disease and eosinophilicesophagitis / Koop, Madisch et al. Update S2k guideline Gastroesophageal reflux disease and eosinophilicesophagitis
One-food versus 4-food elimination diet for pediatric eosinophilicesophagitis: A multisite randomized trial A 6-food elimination diet in pediatric eosinophilicesophagitis (EoE) is difficult to implement and may negatively impact quality of life (QoL). Less restrictive elimination diets may balance QoL and efficacy. We performed a multi-site, randomized comparative efficacy trial of a 1-food
EosinophilicEsophagitis beyond Eosinophils: An Emerging Phenomenon Overlapping with EosinophilicEsophagitis, a CIA Update. Having long been considered the mainstay in eosinophilicesophagitis (EoE) diagnosis and pathogenesis, the role of eosinophils has been questioned and might be less important than previously thought. It is well known now that EoE is a Th2-mediated disease with many more
Worsening disease severity as measured by I-SEE associates with decreased treatment response to topical steroids in eosinophilicesophagitis patients. The index of severity for eosinophilicesophagitis (I-SEE) grades eosinophilicesophagitis (EoE) severity across several domains. We assessed associations between EoE features and severity by I-SEE at diagnosis, and baseline I-SEE and outcomes
Cutaneous Ceramide Synthesis is Dysregulated in Pediatric EosinophilicEsophagitis. Eosinophilicesophagitis (EoE), like atopic dermatitis (AD), is a disease of epithelial barrier dysfunction. The predisposing factors remain under investigation and few links between the skin and esophagus are known. There are no surrogate markers for EoE risk. We evaluated ceramide levels in the skin of children
Factors associated with treatment response in eosinophilicesophagitis patients: Experience from a pediatric tertiary care center. Eosinophilicesophagitis (EoE) is a disease characterized by eosinophilic inflammation of the esophagus and associated esophageal dysfunction with increasing worldwide prevalence. Clinical presentation is nonspecific and varies with age, with limited studies
Dupilumab is efficacious for eosinophilicesophagitis irrespective of prior swallowed budesonide or fluticasone, or prior treatments used alongside swallowed topical corticosteroids: results from the phase 3, randomized, placebo-controlled, LIBERTY EoE T Standard treatments for eosinophilicesophagitis (EoE) may present adherence, tolerance, and efficacy challenges. Dupilumab 300 mg weekly
Patient experience with eosinophilicesophagitis symptoms and impacts on daily life based on in-trial qualitative interviews. Eosinophilicesophagitis (EoE), a chronic immune-mediated progressive disease, causes dysphagia, food impaction, abdominal pain, vomiting, and heartburn. EoE requires long-term monitoring and can affect quality of life owing to its symptoms and associated emotional
Symptomatic Improvement in Adults and Adolescents With EosinophilicEsophagitis Requires Higher Systemic Dupilumab Exposure Than Histologic Response. We assessed potential mechanisms behind the requirement for more frequent dupilumab dosing in eosinophilicesophagitis (EoE) compared with other approved indications. Results for the phase 3 LIBERTY EoE TREET study coprimary endpoints (proportion